Source: ARUP Laboratories
SALT LAKE CITY—ARUP Laboratories now provides a blood test for phosphorylated tau 217 (pTau 217) to assist in identifying whether cognitive decline symptoms in patients ages 60 years and older are related to Alzheimer’s disease (AD) pathology. As this biomarker can be detected in blood, this test is a minimally invasive and broadly accessible diagnostic tool that may facilitate earlier detection of AD.
“The advent of disease-modifying therapies has accelerated the need for early diagnosis since diagnostic delays for Alzheimer’s disease could adversely affect outcomes,” said Heather Nelson, PhD, DABCC, ARUP medical director of Clinical Chemistry. “This test offers a less invasive and more accessible way to provide evidence of AD pathology than alternate means.”
According to the Alzheimer’s Association, AD is the most common cause of dementia, accounting for 60–80% of cases, and brain changes may begin 20 years or more before symptoms start. These brain changes include the accumulation of beta-amyloid and tau proteins.
ARUP validated the pTau 217 test using carefully characterized samples from Eli Lilly and Company’s Phase 3 TRAILBLAZER-ALZ 2 trial. The validation cohort included blood specimens and results from amyloid positron emission tomography (amyloid-PET) imaging of 524 individuals.
Related Posts
Spatial Analysis
Snapshots of Health Innovation From the Edison Awards
Building the Tools Parkinson’s Disease Research Needs
A Q&A with Kishore Malyavantham, PhD, VP of R&D at Quanterix and Co-Investigator, PD-BUILD Quanterix has been named a Co-Investigator institution in PD-BUILD (Biomarker Utilization, Innovation, and Laboratory-to-Deployment), a new project…
Quanterix Named to ASAP CRN 2026 PD-BUILD Program with MJFF Support
Part of a global effort to advance Parkinson’s disease biomarkers through standardized, scalable assay development Quanterix has been selected as a Co-Investigator institution in the PD-BUILD program, part of the…
Neurology
Why biomarkers are no longer supplemental
Quanterix makes the case with ctDNA in oncology, p-tau217 in Alzheimer’s and a lab model built for longitudinal, regulatory-grade data. Biomarkers have moved from “nice-to-have” to the backbone of drug…
Neurology
Preparing The Market for Blood-Based Biomarkers
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for patients and clinicians. Watch the full…
Neurology
Challenges of Positioning an Ultra-Sensitive Platform
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed challenges in positioning Simoa in the precision health market, stressing its accuracy and reliability in diverse populations. Watch the full…
Neurology
Translating Complex Scientific Findings into Actionable Insights
Shana Tetrault, PhD, Director of Product Marketing at Quanterix, discussed translating complex scientific findings into actionable insights for healthcare providers and stakeholders, emphasizing the importance of early disease detection. Watch…
Neurology
AI and the rise of blood-based biomarkers heralds new era for neurological diagnostics
Advances in blood-based biomarkers are transforming early and accurate Alzheimer’s disease detection, offering less invasive, cost-effective alternatives to traditional diagnostic methods. Quanterix, a company working at the very frontiers of…